(44.200.249.42)
Users online: 10213     
Ijournet
Email id
 

Indian Journal of Public Health Research & Development
Year : 2019, Volume : 10, Issue : 10
First page : ( 2076) Last page : ( 2081)
Print ISSN : 0976-0245. Online ISSN : 0976-5506.
Article DOI : 10.5958/0976-5506.2019.03156.5

The Role of Preoperative Subconjunctival Bevacizumab on Recurrence Rate of Primary Pterygium

Dawood Yousif Farhan1,*

Department of Ophthalmology, College of Medicine, University of Anbar, Anbar, Iraq

1Department of Ophthalmology, Ibn Al Haitham Teaching Eye Hospital, Baghdad, Iraq

*Corresponding Author: Yousif Farhan Dawood, ABHS (CABOphth), ICO (Camb), MD Department of Ophthalmology, Ibn Al Haitham Teaching Eye Hospital, Baghdad, Iraq, Email: yf_ds@yahoo.com

Online published on 23 December, 2019.

Abstract

To assess the value of one week preoperative subconjunctival injection of bevacizumab on the surgical management of primary pterygia and also to evaluate the rate of recurrence after excision. This is experimental clinical trial included110 eyes of 110 patients (59 males and 51 females) with a mean age of (49.62 ± 16.54 years), range (27–68) had primary pterygia. The dose of bevacizumab was a 1.25 mg (0.05 ml) one week before pterygium surgery. Surgery was done using excision with direct conjunctival suturing technique. All pterygia were followed up for 6 months.

Top

Keywords

Bevacizumab, P terygium, Recurrence.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
733,139,451 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.